Project Grant R21AG089947
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Institute on Aging (NIA) awarded a $483,346 Project Grant to Meganano Diagnostics Inc. under the Aging Research Federal Grant Program (CFDA 93.866) for the development of an RT-qPCR assay for early diagnosis of Alzheimer's disease (AD). The project aims to leverage changes in T cell receptor (TCR) clonality in peripheral blood mononuclear cells (PBMCs) as a potential biomarker for early AD detection. Preliminary research by Meganano Diagnostics has demonstrated increased TCR...
- The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...
- This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $506,061 to Redwood Neuro Inc. to develop an innovative blood-based diagnostic platform called SIMOLISA. The goal is to revolutionize Alzheimer's disease (AD) diagnostics by enabling ultra-sensitive and affordable detection of critical AD biomarkers such as p-tau proteins and β-amyloid. Unlike current high-cost systems, SIMOLISA utilizes cost-effective materials and...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $320,511 project grant to TRU Diagnostics Inc. to develop a novel diagnostic tool for chronic diseases. The project aims to create a "non-stochastic W function epigenomic roadmap" using systems-based dynamic modeling to capture the shifting homeostatic set points of epigenetic markers over time. This transformative approach aims to enable personalized, dynamic health forecasts...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded Adeptrix Corp. a $499,940 Project Grant on Sep 11, 2025 to develop TAUTRACE, an ultrasensitive immunoassay platform for quantifying distinct molecular forms of the tau protein in cerebrospinal fluid and plasma at femtogram/milliliter levels. This innovative technology enables the detection of single ions, allowing for the quantification of tau proteoforms as critical Alzheimer's disease...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...
- The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to investigate the presence of Alzheimer's disease (AD) biomarkers in nasally exhaled breath. The $440,000 award to Northwestern University will fund research to test the hypothesis that neural proteins associated with AD, such as tau and beta-amyloid, can be detected and quantified in nasally exhaled breath samples. The 2-year project period runs from...
- The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
- This federal Project Grant award of $3,080,520.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias (ADRD) using resting-state functional magnetic resonance imaging (rs-fMRI) data and machine learning. The research aims to address limitations of current ADRD biomarkers by leveraging the dynamics of functional connectivity networks and accounting for heterogeneity...